DARZALEX: payments to doctors
Payments that named DARZALEX as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $13.2M
- Providers
- 17,241
- Transactions
- 99,976
- Average per transaction
- $132
The per-transaction average — $132 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 17,241 providers the average total is $764, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Johnson & Johnson | $11,334,167 | 86.0% |
| Janssen Global Services, LLC | $709,401 | 5.4% |
| Janssen Scientific Affairs, LLC | $579,293 | 4.4% |
| Janssen Research & Development, LLC | $548,814 | 4.2% |